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ABSTRACT
Objectives: To investigate whether adding letrozole in the early follicular phase of a 
gonadotropin-releasing hormone (GnRH) antagonist (GA) stimulation cycle improves in vitro
fertilization (IVF) outcomes in poor responder patients.
Material and methods: To be included in this study, patients had to have had at least one 
previous GA cycle and a subsequent GA cycle with added early follicular phase letrozole 
(LzGA). A total of 41 poor responder patients were identified based on the Bologna criteria.
Results: The LzGA group had a lower dosage of follicular stimulating hormone (FSH) (p = 
0.001), the duration of stimulation days (p = 0.015) and the duration of GnRH antagonist 
stimulation days (p = 0.033) when compared with controls. Comprehensive analysis of the 
cycle characteristics showed that the number of oocytes retrieved, the number of MII oocytes 
retrieved, the number of fertilized oocytes, and the fertilization rate were significantly higher 
in the LzGA cycle (p = 0.041, p = 0.019, p = 0.008, p = 0.01, respectively). The rate of cycle 
cancellation was lower in the LzGA group (24.4%) than in the GA group (48.8%), (p < 
0.001). Although LzGA administration demonstrated a trend toward improved implantation 
and clinical pregnancy rates, this was an insignificant trend (p = 1.000, p = 0.177, 
respectively).
Conclusions: Adjunctive letrozole administration seems to restore an IVF cycle by improving
the cycle characteristics and reducing the total gonadotrophin dosage.
Key words: letrozole; ovarian stimulation; poor response; diminished ovarian reserve; 
antagonist cycle
INTRODUCTION
Diminished ovarian reserve (DOR) is defined as the reduced ability to achieve 
pregnancy and poor ovarian response to gonodotropin stimulation compared with women of a 
similar age [1]. In most patients, DOR remains unexplained but may be caused by advanced 
age, previous ovarian surgery, severe endometriosis, and environmental or genetic factors [2, 
3]. DOR is often related to poor ovarian response to standard ovulation induction protocol and
manifests as poor fertility results even when assisted reproductive techniques (ART) are used. 
Reduced implantation rate, decreased pregnancy rate, increased gonadotrophin use, and 
increased cycle cancellation are some of the main challenges in these patients.
Numerous investigations have been published about the management of poor ovarian 
responders, and they have proposed various stimulation protocols to improve pregnancy 
outcomes [4–7]. Increased gonadotrophin use, gonadotropin-releasing hormone (GnRH) 
agonist flare-up protocols, natural cycle in vitro fertilization (IVF), and adjuvant therapies 
have been studied [8, 9]. Advised adjuvant therapies include growth hormone, aspirin, 
pyridostigmin, L-arginine, androgen supplements (testosterone and dehydroepiandrosterone), 
and androgen-modulating agents (letrozole and anastrozole). However, there is a lack of 
consensus regarding most interventions proposed to improve pregnancy rates in these 
patients.
Letrozole is a potent, highly selective, non-steroidal third-generation aromatase 
inhibitor. It prevents estrogen syntheses by inhibiting the aromatase enzyme activity. The 
resulting decrease in early follicular phase estrogen levels diminishes the negative feedback of
estrogen on follicular stimulating hormone (FSH), consequently causing an augmentation in 
endogenous gonadotropin secretion and stimulation of ovarian follicular growth [10, 11]. The 
other proposed mechanism of action includes raised intraovarian androgens [10]. An increase 
in intraovarian androgens as a result of aromatase inhibition increases the expression of FSH 
receptors on the follicle. Follicular sensitivity to FSH stimulation is thereby augmented [11]. 
Letrozole could successfully induce both ovulation and ovarian stimulation without 
any negative effects on the endometrium in women with polycystic ovary syndrome (PCOS) 
[11, 12]. A few initial studies also showed that, when letrozole is added to a gonadotropin 
ovulation induction in poor responder patients, the ovarian response to FSH increases and the 
gonadotropin doses required for stimulation are decreased [13–15]. However, recent studies 
on the use of letrozole in this patient group have reported inconsistent results [16–21]. This 
study therefore set out to assess whether adding letrozole in the early follicular phase of a 
GnRH antagonist (GA) stimulation cycle improves IVF outcomes in poor responders.
MATERIALS AND METHODS
Patient selection, stimulation protocol, oocyte retrieval and transfer
This retrospective study was conducted at the University of Health Sciences Tepecik 
Education and Research Hospital IVF Centre between January 2017 and December 2018. The
medical records of 246 infertile patients with DOR according to the Bologna criteria of the 
2011 European Society of Human Reproduction and Embryology consensus [22] were 
screened. To be included in this study, patients had to have had at least one previous GA cycle
and a subsequent GA cycle with added early follicular phase letrozole (LzGA). A total of 41 
patients with at least one previous GA cycle followed by an LzGA cycle were identified. Each
patient was included only once. Women with multiple ART cycles who had previously had a 
GA cycle and then had several LzGA cycles were included only for the first GA cycle and the 
subsequent LzGA cycle. Patients with additional infertility factors, such as PCOS, tubal 
factors, and male factors, and who had received the treatment cycles more than six months 
apart were excluded from the study. The study protocol was approved by the Institutional 
Review Board of the University of Health Sciences, Tepecik Education and Research 
Hospital, Izmir, Turkey (approval number 2018/5-11).
Eligible women were evaluated on day two or three of their menstrual cycle by 
transvaginal ultrasound to measure endometrial lining, perform an antral follicle count, and 
exclude the presence of ovarian cysts. Blood samples were also taken for serum FSH, 
luteinizing hormone (LH), estradiol (E2), progesterone (P), and thyroid stimulating hormone 
(TSH). Subsequently, in GA cycle, recombinant FSH (Gonal-F; Merck-Serono, Istanbul) and 
highly purified hMG (Merional; IBSA, Istanbul, Turkey) were used at doses ranging between 
225 and 375 IU/day. The dosages of FSH and hMG were adjusted according to the ovarian 
response. The ovarian response of patients was monitored by transvaginal ultrasound and 
serum E2 levels. A flexible GnRH antagonist protocol (Cetrotide, 0.25 mg/day, Merc-Serono, 
Istanbul, Turkey) was initiated when the average diameter of the leading follicle was 13–14 
mm and/or the serum E2 level was > 350 pg/mL, and the protocol was administered until the 
day of human chorionic gonadotropin (hCG). Recombinant hCG 250 μg (Ovitrelle; Merck-
Serono, Istanbul, Turkey) was administrated to trigger follicle maturation when at least two 
follicles measuring ≥ 17 mm in diameter. 
In subsequent LzGA cycles of patients, hormonal and ultrasonographic measurements 
were taken on day two or three of the menstrual cycle. Letrozole (Femara; Novartis, Istanbul, 
Turkey) at a dose of 5 mg/day (2.5 mg × 2) was initiated on day two or three and continued 
for five days. Ovarian stimulation, use of the GnRH antagonist protocol, and triggering of 
follicle maturation were performed, similarly to their preceding cycles. Oocyte retrieval was 
carried out by transvaginal ultrasonography under general anesthesia 35–36 hours after the 
ovulation trigger. Intracytoplasmic sperm injection (ICSI) was performed for all patients. The 
embryo quality was evaluated in the embryo cleavage stage (2–3 days) and morula-blastocyst 
stage (4–6 days) [23, 24]. Single or double embryos were transferred between day two and 
five under transabdominal ultrasound guidance. The luteal phase was support with 
intravaginal progesterone gel (Crinone; Merc-Serono, Istanbul, Turkey) starting on the day of 
oocyte retrieval and continuing until the 12th week of pregnancy in cases with positive 
pregnancy tests. The ß-hCG serum level was measured to confirm pregnancy on the 12th day 
after embryo transfer. Pregnancy was defined as blood ß-hCG ≥ 20 IU/L. 
Pregnancy
Clinical pregnancy was defined as presence of a fetal heartbeat detected by 
transvaginal ultrasound scan that was performed 4–5 weeks after embryo transfer. 
Implantation rate (IR) was calculated by dividing the number of gestational sacs transplanted 
embryos. Live birth was defined as an infant born alive after the 24th gestational week.
Outcome measurements
The mean cumulative gonadotrophin dosage, mean duration of gonadotrophin 
stimulation days, mean duration of GnRH antagonist stimulation days, mean serum estradiol 
concentration on the day of hCG administration, mean number of oocytes retrieved, mean 
number of mature oocytes (metaphase II oocytes), mean number of fertilized oocytes (mean 
number of 2 pronucleate [2PN] zygotes), fertilization rates, mean number of transferred 
embryos, mean number of transferred embryos for 2–3 days and 5–6 days, clinical pregnancy 
rates, and live birth rates were compared between patients who received the two stimulation 
protocols.
Statistics
Statistical calculations were done using SPSS for Windows version 20.0 (SPSS, 
Chicago,USA). The mean values are expressed as mean ± standard deviation. Statistical 
comparison was carried out by Student’s t-test for continuous variables and the chi-square test
or Fisher’s exact test for categorical variables. A p-value of < 0.05 was considered statistically
significant.
RESULTS
A total of 41 patients, diagnosed as poor responders based on the Bologna criteria, 
were eligible for inclusion. A GA protocol and an LzGA protocol were applied to all patients. 
Table 1 shows the baseline characteristics of the study patients. Their age was 34.3 ± 4.25. 
The duration of infertility was 7.47 ± 5.1 years. Basal hormone levels were similar among 
both cycles except for E2 levels on day three (Tab. 2). 
The used gonadotroin units (2151.21 ± 649.61 vs. 2807.62 ± 1125.55; p = 0.001), the 
number of stimulation days (7.63 ± 1.95 vs. 8.87 ± 2.71; p = 0.015) and the duration of GnRH
antagonist stimulation days (3.97 ± 1.42 vs. 4.80 ± 1.92; p = 0.033) were significantly lower 
in the LzGA cycle than in the GA cycle (Tab. 3). Although the mean number of follicles on 
the trigger day were similar in both cycles, the mean number of retrieved oocytes and the 
number of metaphase II oocytes were significantly higher in LzGA (Tab. 3). The mean peak 
E2 level on the trigger day was also found to be significantly lower in the LzGA cycle than in 
the GA cycle (Tab. 3). LzGA had a higher number of fertilized oocytes and fertilization rate 
(1.82 ± 1.37 vs. 1.19 ± 1.32; p = 0.008, 68.55 ± 35.21 vs. 49.75 ± 44.86; p = 0.01, 
respectively) (Tab. 3). In the GA cycle, the cancellation rate was 48.8%, whereas in the LzGA 
cycle, it was 24.4% (p < 0.001). The causes of cancellation are summarized in Table 4. The 
day on which embryos were transferred and the pregnancy results are shown Table 5. Seven 
clinical pregnancies (17.07%) in the LzGA group and three clinical pregnancies (7.3%) in the 
GA group were recorded. Although LzGA administration was 2.6 times more common in 
clinical pregnancy when compared with GA administration, this was a non-significant trend 
toward higher clinical pregnancy rates in LzGA administration. Of the seven patients who had
clinical pregnancy after LzGA administration, four patients (9.75%) had a live birth.
DISCUSSION
Our results show that, when compared with the previous GA cycle, the succeeding 
LzGA cycle resulted in a significant reduction in the gonadotrophin dose needed for ovarian 
stimulation (OS) and a reduction of the number of stimulation days and the number of GnRH 
antagonist stimulation days. Comprehensive analysis of the cycle characteristics showed that 
the number of oocytes, MII oocytes, and fertilized oocytes retrieved, as well as the 
fertilization rate, were significantly higher in the LzGA cycle. Moreover, lower cancellation 
rates were observed when adding letrozole to subsequent GnRH antagonist cycles. Letrozole’s
positive effects on cycle characteristics, implantation rates, and clinical pregnancy rates 
between cycles were not statistically different. 
Low response to OS, increased gonadotrophin use, reduced implantation rate, and 
decreased prospects of pregnancy are the clinical signs of DOR. The administration of ART 
cycles for these patient populations is one of the largest difficulties for the clinician. Although 
there is not a strong relationship between pregnancy results and the use of letrozole in the first
days of the follicular phase of OS in poor responder patients, various positive effects on the 
cycles have been found [16–21, 25–27]. In a randomized study conducted by Ozmen et al. 
[21], ovarian stimulation with FSH plus letrozole along with GnRH antagonist in poor 
responder patients significantly reduces the necessary doses of gonadotrophin and the cost of 
gonadotrophin stimulation. More recently, Lee et al. [26], analyzed a total of 103 consecutive 
IVF cycles in poor responder patients performed with either FSH plus letrozole along with 
GnRH antagonist or with only FSH along with GnRH antagonist. They reported that the total 
doses of gonadotrophin and days of gonadotrophin administration were significantly lower in 
the letrozole group. In addition, the GnRH antagonist administration days was significantly 
decreased in the letrozole group in this study. A possible explanation is that letrozole increases
ovarian sensitivity to gonadotrophins, and consequently, gonadotropin consumption and the 
duration of stimulation days decrease. In the present study, we demonstrated that the addition 
of letrozole to the early follicular phase of an OS cycle significantly reduced gonadotrophin 
consumption and the duration of the cycle, which is consistent with the above-mentioned 
studies. The GnRH antagonist stimulation days was also shorter in the letrozole group.
When the cycle characteristics are examined, the results of the use of letrozole in the 
early follicular phase and in previous studies are slightly more conflicting [17, 18, 21, 25–27].
Ozmen et al., Goswmi et al., and Ebrahimi et al., reported a comparable number of retrieved 
oocytes in the letrozole group, whereas Lee VC et al., Lee KH et al., and Garcio-Velasco et 
al., reported a significantly higher number of oocytes retrieved [17, 18, 21, 25–27]. 
Consistently with the studies performed by Lee VC et al., Lee KH et al., and Garcio-Velasco 
et al., the present research demonstrated that a significantly increased number of oocytes were
retrieved in the LzGA cycle [25, 26, 17]. The number of metaphase II oocytes was 
significantly higher, consistent with the total number of oocytes retrieved. Similarly, both 
Ozmen et al., and Ebrahimi et al., found the number of metaphase II oocytes to be consistent 
with the total number of oocytes retrieved [21, 27]. However, in the study of Lee et al. [26], 
the number of oocytes retrieved and the number of MII oocytes were not consistent.
IVF treatment results can be expected to improve when significantly more oocytes are 
collected and more MII oocytes are obtained, probably because they augment embryo 
selection for embryo transfer [28, 29]. However, the most previous studies showed similar 
IVF outcomes in the letrozole group. [21, 25–27]. Pregnancy results in the letrozole group did
not differ significantly in any of these studies. Ebrahimi et al. [27], added letrozole to a 
stimulation program for poor responder patients, identified based on the Bologna criteria, and 
there were no significant differences between groups regarding the number of oocytes 
retrieved, fertilization rate, implantation rate, total cycle cancelation rate, and clinical 
pregnancy rate. They suggested that the use of letrozole does not improve clinical outcomes in
poor responder patients. A randomized, controlled trial conducted by Goswami et al. [18], 
reported similar numbers of oocytes retrieved and pregnancy rates between groups, except for
the group with a significantly lower total dose of FSH. These results were consistent with 
what has been stated in various studies [21, 25–27]. Moreover, some studies had 
inconsistencies within themselves [17, 30]. In the Garcia-Velasco study [17], evaluating the 
impact of letrozole as an adjuvant treatment in IVF cycles on low responder patients, there 
was a significant improvement in the implantation rate and the number of oocytes retrieved in 
the group with added letrozole, but there was no significant difference between the groups 
regarding cycle cancelation, fertilization, or pregnancy rates. More recently, Moinid et al. 
[30], compared letrozole plus GnRH antagonist with a placebo plus GnRH antagonist in poor 
responders, and they showed that the total number of retrieved oocytes and of MII oocytes in 
the letrozole-treated group were significantly higher than in the control group. However, there
were no marked differences regarding fertilization rate, implantation rate, or clinical 
pregnancy. In the current study, implantation rates and clinical pregnancy rates were 
comparable between groups despite the higher number of retrieved oocytes, MII oocytes, and 
fertilized oocytes, the increased fertilization rate, and the lower cycle cancellation rates in 
patients receiving letrozole. These results were in accordance with previous studies [17, 30].
In light of these findings, positive results of studies should be evaluated with caution because 
ovarian responses depend on cyclic fluctuations, and patients with a poor response in the first 
cycle might respond normally in the subsequent cycle [31]. Therefore, improvement in cycle 
results with letrozole might be linked to the fluctuation in ovarian response, not to the drug’s 
effect. On the other hand, by blocking the conversion of androstenedione and testosterone to 
estrogen, letrozole might increase endogenous gonadotropin secretion and stimulate ovarian 
follicular growth, leading to a chance to produce more oocytes [10, 11]. The outcomes of the 
present study support the literature that letrozole might improve the cycle characteristics and 
comparable pregnancy results in poor responder patients.
The main criticism of the current study are its retrospective nature and small sample 
size. Retrospective cohort studies are subject to selection bias, recall bias, and unknown 
confounding variables, which may negatively affect the accuracy of the results. Therefore, the
results of the current study need to be interpreted carefully until well-designed, prospective 
randomized trials have been performed. 
CONCLUSIONS
Our findings indicate that adding letrozole in the early follicular phase of a GnRH 
antagonist stimulation cycle has benefits in reducing the required dose of gonadotrophin and 
in improving the success of cycle characteristics in poor responders. Moreover, while there is 
a trend toward improved implantation and clinical pregnancy rates, these results are not 
statistically significant. Nevertheless, it is impossible to say that using letrozole as an adjuvant
agent has no positive effects in poor responder patients during the stimulation cycle. However,
further randomized controlled trials are required to confirm these findings.
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Table 1. Demographic characteristics of patients
n: 41
Age, years (mean ± SD) 34.36 ± 4.25
BMI, kg/m2 ( mean ± SD) 25.12 ± 4.31
Gravida ( mean ± SD) 0.24 ± 0.43
Parity ( mean ± SD) 0
Live birth number ( mean ± SD) 0
Abortion ( mean ± SD) 0.17 ± 0.38
Menstruel cycle duration ( mean ± SD) 26.26 ± 4.82 
Male age, years ( mean ± SD) 37.36 ± 5.26
Duration of infertility, years ( mean ± SD) 8.17 ± 5.10
Values are mean ± SD; SD — standard deviation; BMI — body mass index
Table 2. Basal hormone concentrations in cycles letrozole + GnRH antagonist and 
GnRH antagonist
LzGA cycle GA cycle p
Day-3 serum FSH 
[mIU/mL]
12.82 ± 4.38 11.24 ± 5.31 0.094
Day-3 serum LH 
[mIU/mL]
5.23 ± 3.49 4.64 ± 2.43 0.223
Day-3 serum E2 
[pg/mL]
49.97 ± 23.78 39.69 ± 20.01 0.014
Day-3 serum 
progesterone [ng/mL]
0.82 ± 0.58 0.79 ± 0.49 0.763
TSH [mIU/L] 1.52 ± 0.75 1.49 ± 0.85 0.832
Prolactine [ng/mL] 14.89 ± 5.95 16.56 ± 8.10 0.060
AMH [ng/mL] 0.68 ± 0.33 0.68 ± 0.34 0.323
Antral follicle count 
(n)
4.5 ± 2.73 3.9 ± 2.42 0.276
Values are mean ± SD; p value ≤ 0.05 was considered statistically significant; FSH — follicle 
stimulating hormone; LH — luteinizin hormone; E2 — estradiol; TSH — tiroid stimulating 
hormone; AMH — anti-mullerian hormone; LzGA — letrozole + GnRH antagonist; GA — 
GnRH antagonist
Table 3. Cycle characteristics in cycles letrozole + GnRH antagonist and GnRH 
antagonist
n: 41 LzGA cycle GA cycle p 
Total gonadotrophin 
consumption [IU]
2151.21 ± 649.61 2807.62 ± 1125.55 0.001
Duration of 
stimulation [day]
7.63 ± 1.95 8.87 ± 2.71 0.015
Duration of GnRH 
antagonist 
stimulation [day]
3.97 ± 1.42 4.80 ± 1.92 0.033
Number of follicles 
on day of hCG
2.70 ± 2.13 2.43 ± 1.94 0.572
Oocytes retrieved (n) 2.82 ± 1.37 2.14 ± 0.041 0.041
MII oocytes 
retrieved (n)
2.56 ± 1.46 1.85 ± 0.019
Peak E2 level 
[pg/mL]
557.43 ± 403.58 776.24 ± 376.46 0.002
Fertilized oocytes 
(n)
1.82 ± 1.37 1.19 ± 1.32 0.008
Fertilization rate [%] 68.55 ± 35.21 49.75 ± 44.86 0.01
Values are mean ± SD; p value ≤ 0.05 was considered statistically significant; GnRH — 
gonadotropin releasing hormone; hCG — human chorionic gonadotropin; MII — metaphase 
II; E2 — estradiol; LzGA — letrozole + GnRH antagonist; GA — GnRH antagonist




10 (24.4) 20 (48.8) < 0.001










Poor morphology 1 4
OPU — oocyte pick-up; LzGA — letrozole + GnRH antagonist; GA — GnRH antagonist
Table 5. Days of transferred embryos and pregnancy rates
LzGA cycle GA cycle p
Day 2–3 embryo transfer, n 
(%)
28 (68.3) 19 (39.0) 0.015
Day 5 embryo transfer, n (%) 3 (7.3) 2 (4.9) 1.000
Clinical pregnancyn (%) 7 (17.07) 3 (7.3) 0.177
Implantation rate n (%) 7 (17.07 6 (12.5) 1.000
Live births n (%) 4 (9.75) 0 (0) 0.124
LzGA — letrozole + GnRH antagonist; GA — GnRH antagonist
